Thyrocare Technologies Ltd

Q4 FY26Healthcare Services

Thyrocare Technologies Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹566

Market cap₹9.5K Cr

P/E52.8

Updated23 Aug 2026

Read4 min read

The short version

Specialty testing market opportunity estimated at INR 7,000 to 10,000 crores over 2-3 years, indicating growth potential in specialty and allied services. FY '26 reported a strong profit after tax (PAT) of INR163 crores, up 81% YoY, with EPS of INR2.99, up 64% YoY.

From Thyrocare Technologies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Specialty testing market opportunity estimated at INR 7,000 to 10,000 crores over 2-3 years, indicating growth potential in specialty and allied services.
Q4 FY26 test volume growth surged to ~29%, driven by competitive pricing in biochemistry tests.
Expected mid- to high-teens revenue growth for FY27, primarily volume-driven (~75%), with mix contributing ~25%.
Franchise addition targeted at ~500 per quarter, maintaining steady expansion and increasing average revenue per franchisee due to expanded test menu.
No price hikes planned; growth driven by volume and service mix improvements.

2 more points management made on revenue & sales performance

Profitability & Margins

FY '26 reported a strong profit after tax (PAT) of INR163 crores, up 81% YoY, with EPS of INR2.99, up 64% YoY.
Expect mid- to high-teens growth in test volumes and revenue in FY '27, driven mainly by volume (~75%) and mix (~25%).
Specialty testing is nascent in FY '27; EBITDA margins to remain stable around 32%-34%, with no significant margin expansion expected from specialty until FY '28 onwards.
Operating leverage benefits will be largely reinvested into growth; margin preservation remains a priority.
Franchise expansion and partnership growth, plus new specialty and allied services, underpin future growth.

2 more points management made on profitability & margins

See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

FY'26 capex payout was around INR20-35 crores, relatively low compared to operating cash flow.
Total capitalization during FY'26 was around INR35 crores, including new labs and genomics investments.
Maintenance capex is roughly around INR40 crores, with expansion capex expected in a similar range.
New lab openings: 7 labs added in FY'26 (Bhagalpur, Mandi, Roorkee, Kashmir, Davanagere, Vijaywada, Gwalior).
Focus on franchise addition as a primary growth driver, which is asset-light and limits heavy capex needs.
Investments in genomic and specialty diagnostics with capex estimates around INR5-8 crores.
Major investments for specialty diagnostics are on operational expenditure (field force of ~40 people).

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
The company maintains a strong balance sheet with net cash and investments of INR230 crores and zero debt as of March 31, 2026.
The capital expenditure is being managed within cash flows, with maintenance capex around INR40 crores and calibrated investments in growth areas like genomics and specialty testing.

2 more points management made on fundraising & capital structure

See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention any details about the current or expected order book or pending orders for Thyrocare Technologies Limited. The discussion focuses on: - Market opportunity in specialty testing (INR7,000-10,000 crores estimate). - Growth in insurance business and allied segments. - Franchise expansion running at about 500 franchises per quarter. - Test volume growth and expansion in test menu.

2 more points management made on order book & pipeline

Thyrocare Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹224 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Thyrocare Technologies Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Gaudium IVF (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Thyrocare Technologies Ltd Q4 FY26 results?

What is Thyrocare Technologies Ltd share price analysis?

Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.

Is Thyrocare Technologies Ltd planning capital expenditure?

FY'26 capex payout was around INR20-35 crores, relatively low compared to operating cash flow.

Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.